Nay Nwe Nyein Chan
Associate Research ScientistCards
About
Research
Publications
2026
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
Tarantino P, Kim S, Hughes M, Kusmick R, Smith K, Brasó-Maristany F, Nyein Chan N, Paré Brunet L, Alder L, Garcia-Cortes D, Gomez Tejeda Zanudo J, Pereslete A, Noteware L, Moore H, Van Swearingen A, Li T, Gupta H, D’Amico O, Martini A, Morganti S, Spindel J, Cook C, McLaughlin C, Dvir K, Garrido-Castro A, Sammons S, Files J, Sendrick K, Buck S, Dillon D, Jeselsohn R, Li Y, Cherniack A, LoRusso P, Lustberg M, Vega- León R, Pardo F, Davis J, Mueller C, Corgiat B, Curigliano G, Anders C, Petricoin E, Rimm D, Prat A, Tayob N, Lin N, Tolaney S. Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer. Npj Precision Oncology 2026 PMID: 41826432, DOI: 10.1038/s41698-026-01365-6.Peer-Reviewed Original ResearchMetastatic breast cancerT-DXdBreast cancerTrastuzumab deruxtecanHER2-negative breast cancerTime to next treatmentAssociated with worse outcomesHER2-low diseaseHER2-positive diseaseHER2 immunohistochemical expressionHER2-lowImmunohistochemical subtypesMetastatic settingHER2 assessmentHER2 immunohistochemistrySurvival outcomesImmunohistochemical expressionClinical outcomesTOPO1 expressionWorse outcomesPredictive valueDeruxtecanCancerHER2PatientsQuantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score
He M, Chan N, Liu M, Robbins C, Bates K, Benanto J, Colón-Cartagena L, Kahila M, Zhan H, Krishnamurti U, Moutafi M, Yaghoobi V, Liebler D, Fulton R, Rimm D. Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score. Applied Immunohistochemistry & Molecular Morphology 2026, 34: 143-154. PMID: 41709478, PMCID: PMC13143368, DOI: 10.1097/pai.0000000000001311.Peer-Reviewed Original ResearchTrophoblast cell surface antigen 2Trophoblast cell surface antigen 2 expressionH-scoreBreast cancerQuantitative immunofluorescenceSacituzumab govitecanPathologists' readingsTNBC cohortAntibody-drug conjugate targetsExpression of trophoblast cell surface antigen 2H-score methodSolid tumor typesBreast cancer cohortBreast cancer biopsiesYale-New Haven HospitalBreast cancer samplesCompanion diagnostic testsSurface antigen 2H-score assessmentTumor typesClinical outcomesNew Haven HospitalCancer biopsiesTumor samplesCancer cohortMetabolic characterization of tumor-immune interactions by multiplexed immunofluorescence reveals spatial mechanisms of immunotherapy response in non-small cell lung carcinoma (NSCLC)
Monkman J, Kilgallon A, Lawler C, Tubelleza R, Aung T, Warrell J, Vathiotis I, Trontzas I, Gavrielatou N, Nyein Chan N, Czertok R, Bookstein S, O’Byrne K, Markovits E, Rimm D, Kulasinghe A. Metabolic characterization of tumor-immune interactions by multiplexed immunofluorescence reveals spatial mechanisms of immunotherapy response in non-small cell lung carcinoma (NSCLC). Nature Communications 2026, 17: 837. PMID: 41634004, PMCID: PMC12868679, DOI: 10.1038/s41467-026-68633-8.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaImmune checkpoint inhibitorsProgression-free survivalTumor microenvironmentMultiplex immunofluorescenceAdvanced non-small cell lung carcinomaResponse to ICICell lung carcinomaMultivariate modelMetabolic characterizationTumor-immune interactionsCell-cell proximityCheckpoint inhibitorsICI treatmentICI responseImmunotherapy outcomesImmunotherapy responseLung carcinomaClinical outcomesImmune cellsPatientsMetabolic stateCellular phenotypesImmunofluorescenceTissue neighborhoods
2025
Validation and Prospective Testing of a High-Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology Slides
Chan N, Gaule P, Benanto J, Scott L, Robbins C, He M, Bates K, Khaimova R, Liebler D, Fulton R, Rimm D. Validation and Prospective Testing of a High-Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology Slides. Laboratory Investigation 2025, 105: 104233. PMID: 40882816, PMCID: PMC12500179, DOI: 10.1016/j.labinv.2025.104233.Peer-Reviewed Original ResearchHuman epidermal growth factor receptor 2Selection of patientsT-DXdHER2 expressionApprovals of antibody-drug conjugatesLow-level HER2 expressionAccurate selection of patientsEpidermal growth factor receptor 2Levels of human epidermal growth factor receptor 2Antibody-drug conjugate therapyCore biopsy specimensCompanion diagnostic testsAntibody-drug conjugatesHER2 assaysBiopsy specimensConjugate therapyReceptor 2IHC assayProspective casesPathologist scoresHistopathology slidesDiagnostic testsIHCCoefficient of variation <Pathology laboratoryQuantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS
Zhan H, Chan N, Khaimova R, Aung T, Gaule P, Robbins C, Rimm D. Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS. Breast Cancer Research And Treatment 2025, 213: 273-279. PMID: 40679712, DOI: 10.1007/s10549-025-07781-9.Peer-Reviewed Original ResearchConceptsDuctal carcinoma in situIntermediate-grade ductal carcinoma in situHigh-grade ductal carcinoma in situInvasive carcinomaHER2 expressionHER2 levelsBloom Richardson histological grading systemDuctal carcinoma in situ casesGrading systemFFPE tumor specimensAssessment of HER2 expressionCarcinoma in situHER2 protein expressionInvasive ductal carcinomaNuclear grading systemHER2 expression levelsHistological grading systemNo significant statistical differenceHER2 immunohistochemical scoresHER2 biologyExpression levelsDuctal carcinomaNuclear gradeTumor specimensHistopathological gradeQuantitative Multiplex Immunofluorescence Assay for Trophoblast Cell-Surface Antigen 2 and Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer: Toward Guiding Patient Selection for Antibody-Drug Conjugate Therapies
Robbins C, He M, Chan N, Khaimova R, Bates K, Trontzas I, Scott L, Moutafi M, Coleman C, Hill S, Liebler D, Fulton R, Rimm D. Quantitative Multiplex Immunofluorescence Assay for Trophoblast Cell-Surface Antigen 2 and Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer: Toward Guiding Patient Selection for Antibody-Drug Conjugate Therapies. JCO Precision Oncology 2025, 9: e2500128. PMID: 40669019, PMCID: PMC12490811, DOI: 10.1200/po-25-00128.Peer-Reviewed Original ResearchThis study investigates a multiplex immunofluorescence assay for measuring HER2 and TROP2 in breast cancer, showing potential to guide personalized antibody-drug conjugate therapies.Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma
Aung T, Liu M, Su D, Shafi S, Boyaci C, Steen S, Tsiknakis N, Vidal J, Maher N, Micevic G, Tan S, Vesely M, Nourmohammadi S, Bai Y, Djureinovic D, Wong P, Bates K, Chan N, Gavirelatou N, He M, Burela S, Barna R, Bosic M, Bräutigam K, Illabochaca I, Chenhao Z, Gama J, Kreis B, Mohacsi R, Pillar N, Pinto J, Poulios C, Toli M, Tzoras E, Bracero Y, Bosisio F, Cserni G, Dema A, Fortarezza F, Gonzalez M, Gullo I, Gutiérrez F, Hacihasanoglu E, Jovic V, Lazar B, Olinca M, Neppl C, Oliveira R, Pezzuto F, Pinto D, Plotar V, Pop O, Rau T, Skok K, Sun W, Serbes E, Solass W, Stanowska O, Szasz M, Szymonski K, Thimm F, Vignati D, Vigdorovits A, Prieto V, Sinnberg T, Wilmott J, Cowper S, Warrell J, Saenger Y, Hartman J, Plummer J, Osman I, Rimm D, Acs B. Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma. JAMA Network Open 2025, 8: e2518906. PMID: 40608341, PMCID: PMC12232186, DOI: 10.1001/jamanetworkopen.2025.18906.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesIntraclass correlation coefficientHazard ratioPrognostic studyTIL scorePrognostic valuePrognostic associationRetrospective cohortTumor-infiltrating lymphocyte quantificationAssessment of tumor-infiltrating lymphocytesRetrospective cohort of patientsTumour-infiltrating lymphocyte assessmentMultivariate Cox regression analysisEosin-stained slidesCohort of patientsWhole tissue sectionsCox regression analysisTissue sectionsMelanoma tissue sectionsImmunotherapy outcomesMelanoma managementClinicopathological variablesRetrospective natureTest cohortInterobserver variabilityQuantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer
Trontzas I, He M, Wurtz A, Robbins C, Robinson N, Bates K, Liu M, Aung T, Scott L, Chan N, Burela S, Schillo J, Liebler D, Hill S, Morrison R, Vathiotis I, Syrigos K, Goldberg S, Politi K, Rimm D. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer. Clinical Cancer Research 2025, 31: 2767-2776. PMID: 40047548, PMCID: PMC12213210, DOI: 10.1158/1078-0432.ccr-24-3347.Peer-Reviewed Original ResearchNon-small cell lung cancerAntibody-drug conjugatesAntibody-drug conjugate targetsEGFR mutationsCell lung cancerEGFR expressionQuantitative immunofluorescenceWild-type non-small cell lung cancerLung cancerAssociated with EGFR mutationsAssociated with EGFR expressionTissue microarray cohortAssociation of HER2Management of patientsAssay limitProportion of casesMutation statusTROP2 expressionMicroarray cohortEGFRQuantitative protein expressionTreatment sequencePatientsCell linesWild-type
2024
Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay
Liu M, Vathiotis I, Robbins C, Chan N, Moutafi M, Burela S, Xirou V, Schalper K, Herbst R, Syrigos K, Rimm D. Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay. Modern Pathology 2024, 37: 100556. PMID: 38964502, PMCID: PMC11416319, DOI: 10.1016/j.modpat.2024.100556.Peer-Reviewed Original ResearchNon-small cell lung cancerCases of non-small cell lung cancerNon-small cell lung cancer casesT-DXdCell lung cancerHER2 expressionBreast cancerRare case of non-small cell lung cancerQuantitative immunofluorescenceAntibody-drug conjugate trastuzumab deruxtecanLung cancerHER2 antibody-drug conjugatesNon-small cell lung cancer patientsDetecting HER2 expressionHER2-Targeted TherapyMetastatic breast cancerHER2 protein expressionBreast cancer casesHER2 protein levelsAntibody-drug conjugatesProportion of casesTrastuzumab deruxtecanNSCLC casesFrequency of casesImmunohistochemistry score
2023
Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes
Vesely M, Kidacki M, Gaule P, Gupta S, Chan N, Han X, Yeung J, Chen L. Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes. Journal Of Investigative Dermatology 2023, 144: 106-115.e4. PMID: 37562584, PMCID: PMC11966651, DOI: 10.1016/j.jid.2023.07.008.Peer-Reviewed Original ResearchConceptsCD11b myeloid cellsImmune inhibitory moleculesPD-L1 expressionVISTA expressionMyeloid cellsFuture potential therapeutic targetsPD-L1/B7Tumor microenvironmentInhibitory moleculesMultiplexed quantitative immunofluorescencePrimary cutaneous melanomaImmunosuppressive tumor microenvironmentNegative prognostic biomarkerCurrent clinical trialsPotential therapeutic targetCause mortalityCritical cell typesPD-L1Poor outcomeTreatment of cancerMelanoma recurrenceCutaneous melanomaClinical trialsPrognostic biomarkerT cells
News
News
Get In Touch
Contacts
Email
Mailing Address
Yale School of Medicine
Quantitative Diagnostics in Anatomic Pathology (QDAP) Laboratory , 15 York Street, LMP-B101
NEW HAVEN, CONNECTICUT 06510
United States
Locations
Quantitative Diagnostics in Anatomic Pathology (QDAP) Laboratory
Lab
Laboratory for Medicine and Pediatrics (LMP)
15 York Street, Fl B, Rm 101
New Haven, CT 06510